Compare BWEN & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | PRLD |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 69.1M |
| IPO Year | N/A | 2020 |
| Metric | BWEN | PRLD |
|---|---|---|
| Price | $3.02 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | 279.6K | ★ 491.0K |
| Earning Date | 03-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $153,877,000.00 | $10,500,000.00 |
| Revenue This Year | $11.68 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.07 | ★ N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $1.41 | $0.61 |
| 52 Week High | $4.15 | $4.22 |
| Indicator | BWEN | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 42.81 |
| Support Level | $2.94 | $1.90 |
| Resistance Level | $3.40 | $2.20 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 6.61 | 9.39 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.